Lilly (LLY.N) on Saturday presented Phase III results showing once-weekly Retatrutide promoted weight loss and reduced severity of moderate-to-severe obstructive sleep apnea by 60.6% and knee osteoarthritis pain by up to 73.1% in obese adults.

2026-06-07

Lilly (LLY.N) on Saturday presented Phase III results showing once-weekly Retatrutide promoted weight loss and reduced severity of moderate-to-severe obstructive sleep apnea by 60.6% and knee osteoarthritis pain by up to 73.1% in obese adults.